Valuation: Becton, Dickinson and Company

Market Cap 53.9B 48.27B 44.4B 40.23B 75.21B 5,118B 76.61B 530B 213B 2,692B 202B 198B 8,490B P/E 2026 *
40.3x
P/E 2027 * 23.3x
Enterprise Value 69.78B 62.5B 57.49B 52.09B 97.37B 6,626B 99.19B 686B 275B 3,486B 262B 256B 10,992B EV / Sales 2026 *
3.62x
EV / Sales 2027 * 3.44x
Free-Float
73.18%
Yield 2026 *
2.11%
Yield 2027 * 2.15%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Chief Tech/Sci/R&D Officer 56 2023-12-03
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 53.9B
+1.56%+2.41%-14.09%+11.78% 184B
-0.59%+1.18%+6.44%+36.26% 118B
-6.38%-4.98%-18.07%+7.28% 111B
+3.42%+1.71%-41.92%+7.51% 94.58B
+0.09%-0.05%-2.06%+76.70% 63.13B
-5.48%-5.11%-1.45%+61.88% 55.66B
-0.23%-0.52%+10.73%-22.03% 53.9B
-4.30%-1.64%-12.44%+39.42% 43.42B
+0.58%+2.00%-1.17%-9.88% 34.68B
Average -1.13%+0.06%-8.23%+23.21% 84.27B
Weighted average by Cap. -0.80%+0.24%-10.57%+21.67%

Financials

2026 *2027 *
Net sales 19.29B 17.28B 15.89B 14.4B 26.92B 1,832B 27.42B 190B 76.08B 963B 72.39B 70.86B 3,038B 19.73B 17.67B 16.25B 14.73B 27.53B 1,873B 28.04B 194B 77.8B 985B 74.04B 72.46B 3,107B
Net income 1.41B 1.26B 1.16B 1.05B 1.96B 134B 2B 13.82B 5.55B 70.24B 5.28B 5.17B 222B 2.19B 1.96B 1.81B 1.64B 3.06B 208B 3.12B 21.53B 8.64B 109B 8.23B 8.05B 345B
Net Debt 15.88B 14.23B 13.09B 11.86B 22.16B 1,508B 22.58B 156B 62.65B 793B 59.61B 58.35B 2,502B 13.95B 12.5B 11.49B 10.41B 19.47B 1,325B 19.83B 137B 55.02B 697B 52.36B 51.25B 2,198B
Projected Income Statement - Annual - Becton, Dickinson and Company
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Becton, Dickinson and Company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
197.88USD
Average target price
195.57USD
Spread / Average Target
-1.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Becton, Dickinson and Company